Tuesday, 6 August 2019

Young blood cocktail stops Alzheimer's decline, early clinical trial reports

The company behind a Phase 2 trial of its proprietary young plasma protein formulation says it ...

Alkahest, a California-based biotech start-up, has just revealed some compelling early results from an ongoing Phase 2 trial into the efficacy of its novel formulation of plasma proteins derived from young blood, developed to slow, or even stop, the cognitive decline associated with Alzheimer's disease.

.. Continue Reading Young blood cocktail stops Alzheimer's decline, early clinical trial reports

Category: Medical

Tags:

from New Atlas (Gizmag) https://ift.tt/33lbnZt

No comments:

Post a Comment